GSK Eyes Multiple Myeloma with New T-Cell Tech

GSK has re-entered the oncology arena by acquiring global rights to Chimagen Biosciences' trispecific T-cell engager (TCE) program. This agreement signals GSK's renewed commitment to cancer therapeutics, a field they largely exited over a decade ago. The deal's financial terms include an upfront payment and potential milestone payments that could total up to $750 million.

Under the agreement, GSK will spearhead the development of this TCE asset for multiple myeloma, aiming to initiate Phase I clinical trials in 2027. This collaboration marks the second partnership between GSK and Chimagen, following a 2024 licensing deal for a TCE targeting autoimmune diseases.

The market for TCEs is experiencing significant growth, driven by their proven efficacy in treating cancers like multiple myeloma. Approved drugs such as Tecvayli have demonstrated strong results, and market forecasters predict the US TCE market for multiple myeloma could surpass $10 billion by 2032.

GSK's strategic shift back into oncology aligns with its new CEO's vision to expand its focus beyond blood and women's cancers to include lung, gastrointestinal, and other solid tumors. The company is exploring advanced modalities like ADCs and TCEs to achieve this expansion. Immuno-oncology, the broader category for TCEs, is a rapidly advancing field, with over 60% of ongoing Phase III studies for multiple myeloma classified as such.